摘要
背景：富含亮氨酸的α-2-糖蛋白1（LRG1）是一种新的致癌基因相关基因，已被证明对人类癌症的发展和不良预后很重要。但是，是否参与食管鳞状细胞癌（ESCC）进展尚不清楚。 目的：探讨LRG1在ESCC中的表达水平及其功能影响。 方法：根据ESCC患者的mRNA和蛋白水平评估LRG1的表达。然后，在ESCC中分析了LRG1表达与临床病理变量的相关性。此外，为了阐明LRG1的生物学功能，用LRG1 shRNA转染了Eca109和KYSE150细胞，进行了细胞活力，克隆效率，细胞凋亡和体外侵袭实验。 结果：LRG1在ESCC中显着过表达，并且与更深的浸润深度（T期）和远端转移（M期）有关。 Kaplan-Meier分析表明，ESCC中的LRG1上调与较差的临床生存率（总生存率和无进展生存期）密切相关，所有P <0.001。通过单因素和多因素分析，LRG1被证实是ESCC临床预后的独立不良预后指标。 ESCC细胞中LRG1的下调显着抑制细胞增殖和侵袭，刺激细胞凋亡（所有p <0.01）。 结论：LRG1可能在ESCC的进展中起重要作用，可作为ESCC患者的有希望的预后预测。
关键词: LRG1，食管癌，鳞状细胞癌，预后，增殖，浸润。
图形摘要
[1]
Wang, Y.; Guan, S.; Bi, Y.; Lin, S.; Ma, J.; Xing, Q.; Liu, C.; Zhang, R.; Qu, Z.; Jiang, P.; Chen, X. Survival impact of delaying postoperative radiotherapy in patients with esophageal cancer. Transl. Oncol., 2018, 11, 1358-1363.
[2]
Holmes, R.S.; Vaughan, T.L. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol., 2007, 17, 2-9.
[3]
Wang, X.; Fan, J.C.; Wang, A.R.; Leng, Y.; Li, J.; Bao, Y.; Wang, Y.; Yang, Q.F.; Ren, Y. Epidemiology of esophageal cancer in Yanting - regional report of a national screening programme in China. Asian Pac. J. Cancer Prev., 2013, 14, 2429-2432.
[4]
Pennathur, A.; Gibson, M.K.; Jobe, B.A.; Luketich, J.D. Oesophageal carcinoma. Lancet, 2013, 381, 400-412.
[5]
Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60, 277-300.
[6]
Haupt, H.; Baudner, S. Isolation and characterization of an unknown, leucine-rich 3.1-S-alpha2-glycoprotein from human serum. Hoppe Seylers Z. Physiol. Chem., 1977, 358, 639-646.
[7]
Hoogland, C.; Mostaguir, K.; Sanchez, J.C.; Hochstrasser, D.F.; Appel, R.D. SWISS-2DPAGE, ten years later. Proteomics, 2004, 4, 2352-2356.
[8]
Donnell, L.C.; Druhan, L.J.; Avalos, B.R. Molecular characterization and expression analysis of leucine-rich alpha2-glycoprotein, a novel marker of granulocytic differentiation. J. Leukoc. Biol., 2002, 72, 478-485.
[9]
Serada, S.; Fujimoto, M.; Terabe, F.; Iijima, H.; Shinzaki, S.; Matsuzaki, S.; Ohkawara, T.; Nezu, R.; Nakajima, S.; Kobayashi, T. Serum leucine- rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm. Bowel Dis., 2012, 18, 2169-2179.
[10]
Kobe, B.; Kajava, A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol., 2001, 11, 725-732.
[11]
Saito, K.; Tanaka, T.; Kanda, H.; Ebisuno, Y.; Izawa, D.; Kawamoto, S.; Okubo, K.; Miyasaka, M. Gene expression profiling of mucosal addressin cell adhesion molecule-1+ high endothelial venule cells (HEV) and identification of a leucine-rich HEV glycoprotein as a HEV marker. J. Immunol., 2002, 168, 1050-1059.
[12]
Weivoda, S.; Andersen, J.D.; Skogen, A.; Schlievert, P.M.; Fontana, D.; Schacker, T.; Tuite, P.; Dubinsky, J.M.; Jemmerson, R. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J. Immunol. Method., 2008, 336, 22-29.
[14]
Lynch, J.; Meehan, M.H.; Crean, J.; Copeland, J.; Stallings, R.L.; Bray, I.M. Metastasis suppressor microrna-335 targets the formin family of actin nucleators. PLoS One, 2013, 8e78428
[15]
Wang, X.; Abraham, S.; McKenzie, J.A.G.; Jeffs, N.; Swire, M.; Tripathi, V.B.; Luhmann, U.F.O.; Lange, C.A.K.; Zhai, Z.; Arthur, H.M. LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature, 2013, 499, 306-311.
[16]
Lynch, J.; Fay, J.; Meehan, M.; Bryan, K.; Watters, K.M.; Murphy, D.M.; Stallings, R.L. Mirna-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical tgf- signalling pathway. Carcinogenesis, 2012, 33, 976-985.
[17]
Zhong, D.; Zhao, S.; He, G.; Li, J.; Lang, Y.; Ye, W.; Li, Y.; Jiang, C.; Li, X. Stable knockdown of LRG1 by RNA interference inhibits growth and promotes apoptosis of glioblastoma cells in vitro and in vivo. Tumour Biol., 2015, 36, 4271-4278.
[18]
Liu, Y.; Luo, X.; Hu, H.; Wang, R.; Sun, Y.; Zeng, R.; Chen, H. Integrative proteomics and tissue microarray profiling indicate the association between overexpressed serum proteins and non-small cell lung cancer. PLoS One, 2012, 7 e51748
[19]
Li, Y.; Zhang, Y.; Qiu, F.; Qiu, Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis, 2011, 32, 1976-1983.
[20]
Wang, C.H.; Li, M.; Liu, L.L.; Zhou, R.Y.; Fu, J.; Zhang, C.Z.; Yun, J.P. LRG1 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Oncotarget, 2015, 6, 42118-42129.
[21]
Andersen, J.D.; Boylan, K.L.; Jemmerson, R.; Geller, M.A.; Misemer, B.; Harrington, K.M.; Weivoda, S.; Witthuhn, B.A.; Argenta, P.; Vogel, R.I. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J. Ovarian Res., 2010, 3, 21.
[22]
Yamamoto, M.; Takahashi, T.; Serada, S.; Sugase, T.; Tanaka, K.; Miyazaki, Y.; Makino, T.; Kurokawa, Y.; Yamasaki, M.; Nakajima, K. Overexpression of leucine-rich α2-glycoprotein-1 is a prognostic marker and enhances tumor migration in gastric cancer. Cancer Sci., 2017, 108, 2052-2060.
[23]
Donohoe, C.L.; Phillips, A.W. Cancer of the Esophagus and
Esophagogastric Junction: An 8th Edition Staging Primer. J. Thorac.
Oncol., 2017, 12, 36-42.
[24]
Chen, X.; Xu, W.; Wang, C.; Liu, F.; Guan, S.; Sun, Y.; Wang, X.; An, D.; Wen, Z.; Chen, P.; Cheng, Y. The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma. Am. J. Cancer Res., 2017, 7, 700-714.
[25]
Sun, D.C.; Shi, Y.; Wang, L.X.; Lv, Y.; Han, Q.L.; Wang, Z.K.; Dai, G.H. Leucine-rich alpha-2-glycoprotein-1, relevant with microvessel density, is an independent survival prognostic factor for stage III colorectal cancer patients: a retrospective analysis. Oncotarget, 2017, 8, 66550-66558.
[26]
Wen, S.Y.; Zhang, L.N.; Yang, X.M.; Zhang, Y.L.; Ma, L.; Ge, Q.L.; Jiang, S.H.; Zhu, X.L.; Xu, W.; Ding, W.J. LRG1 is an independent prognostic factor for endometrial carcinoma. Tumour Biol., 2014, 35, 7125-7133.
[27]
Wang, Y.; Chen, C.; Hua, Q.; Wang, L.; Li, F.; Li, M.; Mei, Z.; Zhou, T.; Xiao, B.; Tao, Z. Downregulation of leucine-rich-α-2-glycoprotein 1 expression is associated with the tumorigenesis of head and neck squamous cell carcinoma. Oncol. Rep., 2017, 37, 1503-1510.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
30
4